Is the biopharma industry's reputation headed back to the basement? New research finds a backslide underway.

‘Phar­ma burnout’: In­dus­try rep­u­ta­tion slumps in first half of 2022, study finds

The bio­phar­ma in­dus­try rep­u­ta­tion is slid­ing again — and alarm­ing­ly fast. The phar­ma­ceu­ti­cals, biotech­nol­o­gy and life sci­ences cat­e­go­ry fell al­most 3 points (2.9) be­tween the first and sec­ond quar­ter of 2022, ac­cord­ing to cor­po­rate rep­u­ta­tion mon­i­tor Rep­Trak.

While a two- or three-point drop may not seem sig­nif­i­cant, Rep­Trak points out that its his­tor­i­cal da­ta “warns us that a 1-point drop of­ten re­sults in a 4-5% drop in sup­port.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.